欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (5): 541-545.doi: 10.12092/j.issn.1009-2501.2019.05.010

• 基础研究 • 上一篇    下一篇

miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究

郑中秋1,谢伯剑1,崔斌斌1,柯抒晨2,林 义2   

  1. 1浙江省台州医院,台州 317000,浙江;2温州医科大学附属第三医院妇产科,温州 325200,浙江
  • 收稿日期:2018-12-24 修回日期:2019-04-22 出版日期:2019-05-26 发布日期:2019-05-28
  • 作者简介:郑中秋,女,硕士,主治医师,研究方向:乳腺甲状腺外科。 Tel:13666857706 E-mail:zhengzq@enzemed.com
  • 基金资助:

    浙江省自然科学基金(TU20155645365)

miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells

ZHENG Zhongqiu 1, XIE Bojian 1, CUI Binbin 1, KE Yichen 1, LIN Yi 2   

  1. 1 Taizhou Hospital of Zhejiang Province, Taizhou 317000, Zhejiang, China; 2 Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, Zhejiang, China
  • Received:2018-12-24 Revised:2019-04-22 Online:2019-05-26 Published:2019-05-28

摘要:

目的:探讨miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制。方法:随机选取2015年10月至2018年5月在本院进行手术切除的乳腺癌患者58例,取乳腺癌组织和癌旁组织提取细胞DNA,用荧光定量PCR的方法检测miR-106 b的表达量。购买乳腺癌MCF-7细胞系,构建促进miR-106 b表达的高表达组、抑制miR-106 b表达的低表达组细胞系。用不同浓度的顺铂处理,48 h后观察在体外和裸鼠皮下肿瘤的受抑制情况。荧光定量PCR法检测PTEN/PI3K/AKT信号通路相关基因的表达。结果:荧光定量PCR显示乳腺癌组织中miR-106 b的相对表达量高于癌旁组织(P<0.05)。在20、30和40 μmol/L浓度时,对照组和高表达组的相应浓度下的细胞抑制率均显著高于低表达组,对照组相应浓度下的细胞抑制率均显著高于低表达组(P<0.05)。在20、30和40 μmol/L浓度时,对照组和高表达组的相应浓度下的荧光强度均低于低表达组,且高表达组均显著低于对照组(P<0.05)。低表达组PTEN的相对表达量显著低于对照组,而高表达组PTEN的相对表达量显著高于对照组(P<0.05)。低表达组的PI3K和AKT的相对表达量显著高于对照组,高表达组的PI3K和AKT的相对表达量显著低于对照组(P<0.05)。结论:miR-106 b在乳腺癌中高表达,且表达量越高,乳腺癌细胞对顺铂的化疗敏感性越强。

关键词: miR-106 b, 乳腺癌, 顺铂, 化疗敏感性

Abstract:

AIM: To explore miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells. METHODS: Fifty-eight cases of breast cancer patients diagnosed and treated in our hospital from October 2015 to May 2015 were randomly selected. Breast cancer tissue and paracancer tissue were taken. Cellular DNA was extracted from breast cancer tissues and adjacent tissues, and the expression level of miR-106 b was detected by real-time PCR. MCF-7 cell lines of breast cancer were purchased to construct the high-expression group promoting the expression of mir-106 b and the low-expression group inhibiting the expression of miR-106 b. After 48 h treatment with cisplatin at different concentrations, the inhibition of tumors in vitro and subcutaneous in nude mice was observed. Fluorescence quantitative PCR was used to detect the expression of PTEN/PI3K/AKT signaling pathway related genes.RESULTS:Real-time PCR showed that the relative expression of miR-106 b in breast cancer tissues was higher than that in adjacent tissues (P<0.05). At 20, 30 and 40 μmol/L concentrations, the cell inhibition rates of the control group and the high expression group were significantly higher than those of the low expression group, and the cell inhibition rate of the control group was significantly higher than that of the low expression group (P<0.05). At the concentrations of 20, 30 and 40 μmol/L, the fluorescence intensity at the corresponding concentrations in the control group and the high expression group was lower than that in the low expression group, and the high expression group was significantly lower than the control group (P<0.05). The relative expression of PTEN in the low expression group was significantly lower than that in the control group, while the relative expression of PTEN in the high expression group was significantly higher than that in the control group (P<0.05). The relative expression levels of PI3K and AKT in the low expression group were significantly higher than those in the control group, and the relative expression levels of PI3K and AKT in the high expression group were significantly lower than those in the control group (P<0.05). CONCLUSION: miR-106 b is highly expressed in breast cancer, and the higher the expression, the more sensitive breast cancer cells are to cisplatin chemotherapy.

Key words: miR-106 b, breast cancer, cisplatin, chemotherapy sensitivity

中图分类号: